Almac joins clinical supply blockchain working group

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/LeoWolfert)
(Image: Getty/LeoWolfert)

Related tags: Almac, Almac group, Blockchain, Supply chain

Almac joins a working group made up of clinical supply chain industry members, in order to contribute to the use case discussion about blockchain technology.

The Northern Ireland-headquartered contract manufacturing organization (CMO), Almac, recently announced its participation in the Global Clinical Supply Blockchain Working Group​ (GCSBWG).

Led by Pfizers and Biogen, the group is a collaboration between companies aiming to explore the applicability of blockchain technology in the industry.

Blockchain technology “is new to everyone, including Almac,”​ a spokesperson for the company told us.

The group is an opportunity for key contributors from all stages of the clinical supply chain – academia, clinical sites, pharma companies, and suppliers – to “combine first hand experience and ensure that the most relevant blockchain use cases possible are being prioritized and explored,”​ the spokesperson added.

Asked about Almac’s contribution to the group, the spokesperson noted that the company’s “critical role in orchestrating clinical trials across the globe” provides it with “a unique perspective that we’re proud to contribute to the ongoing use case discussion.”

Andrew Hillis, VP and group head of information services at Almac, commented: “The rapid adoption of blockchain technology, coupled with its clear applicability to the clinical supply chain, make this project extremely timely and relevant to meeting the future challenges of our industry.”

To date, the working group has designed KitChain, a proof-of-concept iOS-based software application to enhance communication among clinical supply chain participants.

The ultimate aim of the group, according to Almac, would be to create a messaging and notification platform able to support the performance requirements of the whole clinical supply chain.

Further activity of the group to date is included in a whitepaper entitled “Transforming Pharmaceutical Clinical Supply Messaging with BlockChain,”​ which was published after the completion of the group’s Phase I operations.

Related news

Show more

Related products

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more